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Primary features of the flavivirus Kunjin (KUN) subgenomic replicons include continuous noncytopathic
replication in host cell cytoplasm and the ability to be encapsidated into secreted virus-like particles (VLPs).
Previously we reported preparation of RNA-based KUN replicon vectors and expression of heterologous genes
(HG) in cell culture after RNA transfection or after infection with recombinant KUN VLPs (A. N. Varnavski
and A. A. Khromykh, Virology 255:366–375, 1999). In this study we describe the development of the next
generation of KUN replicon vectors, which allow synthesis of replicon RNA in vivo from corresponding plasmid
DNAs. These DNA-based vectors were able to direct stable expression of b-galactosidase (b-Gal) in several
mammalian cell lines, and expression remained high (;150 pg per cell) throughout cell passaging. The
applicability of these vectors in vivo was demonstrated by b-Gal expression in the mouse lung epithelium for
at least 8 weeks after intranasal inoculation and induction of anti-b-Gal antibody response after intramuscular
inoculation of the b-Gal-encoding KUN replicon DNA. The noncytopathic nature of DNA-based KUN replicon
vectors combined with high-level and stability of HG expression in a broad range of host cells should prove
them to be useful in a variety of applications in vitro and in vivo.
Development of gene expression vectors based on sub-
genomic replicons of positive-strand RNA viruses has gained
much attention over the last decade (11, 32). Genomes of the
alphaviruses Semliki Forest virus (SFV) (7, 29), Sindbis (SIN)
virus (1, 10, 15) and Venezuelan equine encephalitis virus (12,
37), as well as the poliovirus genome (34, 36), have all been
used. An important characteristic feature of these systems is
the ability of replicon RNA to self-replicate, thereby amplify-
ing the input template in the host cell. This amplification in
turn leads to increased production of encoded proteins. Rep-
licon RNAs can be delivered into host cells by direct transfec-
tion with RNA transcripts produced in vitro from correspond-
ing plasmid DNAs (20, 47) or by infection with virus-like
particles (VLPs) containing encapsidated replicon RNAs (10,
12, 29, 37). Alternatively, they can be transcribed from trans-
fected replicon-encoded plasmid DNAs utilizing cellular RNA
polymerase II transcription machinery (1, 7, 14, 15). It was
shown that replicon-based DNA vectors produced higher lev-
els of encoded heterologous proteins than conventional plas-
mid DNA expression vectors and also elicited greatly enhanced
immune responses (7, 19).
Applications for most of the alphavirus and poliovirus rep-
licon vectors have been limited to only short-term transient
expression due to the cytopathic effects (CPE) induced by
vector replication in mammalian cells (18). To address this
problem, noncytopathic SIN virus replicon-based vectors con-
taining the puromycin resistance gene were developed by iso-
lation of SIN replicon mutants adapted to puromycin selection
in BHK cells (1, 17). However, the use of these vectors is
restricted by a number of limitations, such as a narrow host
range, relatively low levels of heterologous gene (HG) expres-
sion, and some instability of expression in cell populations
during passaging (1).
We have been developing a gene expression system based on
subgenomic replicons of another RNA virus, the flavivirus
Kunjin (KUN), containing deletions in the structural region of
the genome (25). In contrast to the alphavirus and poliovirus
replicons, as well as full-length KUN RNA, replication of
KUN replicons in mammalian cell cultures did not produce
any apparent CPE (25). Recently we reported the construction
and use of RNA-based KUN replicon vectors for HG expres-
sion in cell culture after the direct transfection of in vitro-
synthesized recombinant KUN replicon RNAs or after infec-
tion with recombinant KUN VLPs (43). In this study we
describe the development of DNA-based KUN replicon vec-
tors and demonstrate their ability to direct high-level pro-
longed HG expression in a range of cell lines and in vivo.
Moreover, we show the induction of antibody response against
a KUN vector-encoded HG after immunization of mice with
the corresponding KUN replicon DNA construct. These non-
cytopathic DNA-based KUN replicon expression vectors
should be useful for a variety of applications both in vitro and
in vivo.
MATERIALS AND METHODS
Cells. BHK21 (baby hamster kidney), Vero (green African monkey kidney),
HepG2 (human hepatocarcinoma), HeLa (human cervical epitheloid carcino-
ma), A172 (human glioblastoma), and 293 (transformed human embryonal kid-
ney) cells were grown in Dulbecco’s minimal essential medium (Gibco BRL)
supplemented with 10% fetal bovine serum. HEp-2 (human larynx epidermoid
carcinoma) cells were grown in RPMI 1640 medium supplemented with 15 mM
HEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid) and 5% fetal bo-
vine serum.
Plasmid construction. All the molecular constructs were prepared by using
standard molecular biology techniques (3), and their sequences were confirmed
by restriction digest analysis and/or sequencing. All the PCR amplifications for
subsequent cloning were performed with high-fidelity Pfu DNA polymerase
(Stratagene). The sequences of primers used in preparation of KUN replicon
vectors and constructs are shown in Table 1.
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(i) RNA-based KUN replicon constructs. The C20Ubrep plasmid was pre-
pared by cloning the mouse Ubiquitin (Ub) gene sequence (16), PCR amplified
from the plasmid pRB269 (5) by using Ub_F and Ub_R primers with incorpo-
rated XbaI and SpeI restriction sites, respectively (Table 1), into the SpeI site of
the previously reported C20DX2Arep plasmid (43) (Fig. 1A). To construct the
C20UbHDVrep plasmid, the hepatitis delta virus antigenomic ribozyme (HDVr)
sequence (35) followed by the simian virus 40 (SV40) polyadenylation signal
(pA) was inserted immediately downstream of the last nucleotide of the KUN
replicon sequence. The fragment containing the last 1,331 nucleotides of the
KUN replicon sequence followed by the HDVr/SV40-pA cassette was produced
in a fusion PCR (23) using NS5dGDD_F, 39UTRHDV, and SV40pA_R primers
(Table 1) and two plasmid templates, pTMSV5A (obtained from Tom Mac-
naughton, Sir Albert Sakzewski Virus Research Centre, Brisbane, Australia) and
C20DXrep (26). The resulting PCR product was digested with XmaI (59 end;
KUN NS5 sequence) and XhoI (39 end) and cloned into the XmaI-XhoI-digested
C20Ubrep DNA, producing the C20UbHDVrep construct (see Fig. 1A).
(ii) DNA-based KUN replicon constructs. The pKUNrep1 plasmid was
prepared by replacing the SP6 promoter in the RNA-based construct
C20UbHDVrep with the cytomegalovirus (CMV)-derived immediate-early en-
hancer/promoter region (8). The fragment containing the CMV sequence fol-
lowed by the 59 end of the KUN replicon sequence was produced in a fusion PCR
(23) using CMV_F, CMV59UTR, and FMDV2A_R primers (Table 1) and the
plasmid templates pCI (Promega) and C20Ubrep. The resulting PCR product
was digested with EagI (39 end) and cloned into the C20UbHDVrep plasmid
digested with the NruI and EagI endonucleases, producing the pKUNrep1 vector
(see Fig. 1A and 2). The pKUNrep2 vector was prepared by deletion of the Ub
gene from the pKUNrep1 vector, i.e., by digestion with the AscI and MluI
endonucleases and subsequent religation (Fig. 2). The pKUNrep2(dGDD) con-
struct with the deletion of the RNA polymerase motif GDD in the NS5 gene
(designated as dGDD) was prepared by replacing the EcoRV-XmaI restriction
fragment in the pKUNrep2 plasmid with the EcoRV-XmaI fragment derived
from the FLdGDD plasmid (26). The pKUNrep3 vector was constructed by
cloning the puromycin N-acetyltransferase (PAC; 42) gene followed by the foot-
and-mouth disease virus autoprotease 2A (FMDV-2A; 40) sequence into the
NsiI site of the pKUNrep2 vector (Fig. 2). The cloned PAC-FMDV-2A fragment
was PCR amplified from the C20/GFPpac/2Arep plasmid (to be described else-
where) by using PacPst_F and 2AMluNsi_R primers with incorporated PstI and
NsiI restriction sites, respectively (Table 1). The pKUNrep4 vector was prepared
by substituting the second FMDV-2A sequence in the pKUNrep3 vector with the
encephalomyelocarditis virus internal ribosome entry site (IRES) sequence, PCR
amplified from the C20DX/CAT/IRESrep plasmid (43) by using NsiIRES_F and
dNS1H3_R primers with incorporated NsiI and SphI restriction sites, respec-
tively (Table 1). The Escherichia coli b-galactosidase (b-Gal) gene, which was
PCR amplified from the C20DX/b-gal/2Arep construct (43) by using NsiLacZ_F
and NsiLacZ_R primers with incorporated NsiI restriction sites (Table 1), was
cloned as a reporter gene into the NsiI sites of the pKUNrep2, pKUNrep2
(dGDD), pKUNrep3, and pKUNrep4 vectors, producing the pKUNbrep2,
pKUNbrep2(dGDD), pKUNbrep3, and pKUNbrep4 constructs, respectively.
DNA transfection and selection of stably expressing cell cultures. Plasmid
DNAs were transfected with FuGENE 6 transfection reagent (Boehringer
Mannheim) essentially as described by the manufacturer. For HG expression and
stable cell line selection, ;0.8 mg of DNA was used with 2 ml of FuGENE 6 to
transfect ;1.3 3 105 cells in 16-mm-diameter wells (of a 24-well cell culture
plate). Cells transfected with the plasmids containing the PAC gene, a selection
marker conferring resistance to the antibiotic puromycin, were incubated in the
appropriate growth medium for ;48 h after transfection, followed by their
selection with puromycin (Sigma) added to the medium at 1 to 5 mg/ml.
Metabolic labeling, RIP, and Northern blot hybridization. Metabolic labeling
of BHK21 cells in 35-mm-diameter dishes with [35S]methionine-cysteine at ;30
h after transfection with ;2 mg of pKUNrep2 or pKUNrep2(dGDD) plasmid
DNAs was performed essentially as described previously (27). Actinomycin D
(ACD) was added, where indicated, for 1 h prior to radiolabeling at 10 mg/ml and
during the 1-h labeling at 3 mg/ml. Radioimmunoprecipitation (RIP) analysis of
the labeled cell lysates with KUN anti-NS3 antibodies was performed as previ-
ously described (27). Northern blot hybridization of 10 mg of total RNA isolated
from BHK21 cells at ;36 h after transfection with pKUNrep2 or pKUNrep2
(dGDD) plasmids was performed with the [32P]dCTP-labeled probe represent-
ing the 39-terminal 761 nucleotides of the KUN cDNA (24) as described previ-
ously (25, 27).
In situ b-Gal reaction staining and b-Gal assay. Expression of b-Gal in
transfected cells was detected by staining cell monolayers with 5-bromo-4-chloro-
3-indolyl-b-D-galactopyranoside (X-Gal) at 30 to 40 h after transfection with
corresponding b-Gal-encoding constructs or by determination of b-Gal activity
in lysates of these cells by using the b-Galactosidase Enzyme Assay System
(Promega, Madison, Wis.) essentially as described by the manufacturer.
In vivo DNA administration and antibody titration. Six- to 9-week-old female
BALB/c mice anesthetized by intraperitoneal injection with ketamine-xylazine
were inoculated intranasally with ;5 mg of the pKUNbrep2 DNA complexed
with 15 ml of FuGENE 6 transfection reagent (Boehringer Mannheim) in a total
volume of 100 ml. Primary and booster intramuscular (i.m.) immunizations were
performed by injection of 25 mg of pKUNrep2, pKUNbrep2, pSCAb, or pCMVb
DNA in phosphate-buffered saline (PBS) in a total volume of 80 ml into the
quadricep muscles of 6- to 9-week-old female BALB/c mice. Booster immuni-
zations were performed 5 weeks later.
The immunized mice were bled 4, 8, and 11 weeks postpriming, and anti-b-Gal
immunoglobulin G (IgG) responses were determined by enzyme-linked immu-
nosorbent assay (ELISA) using purified recombinant b-Gal protein (Promega)
as follows. Wells of microtiter plates were incubated with 0.2 mg of b-Gal/ml in
50 ml of coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) overnight at
4°C, blocked with 50 ml of PBS containing 1% skim milk powder and 1% sucrose
(PBS/MP/S) for 6 to 7 h at 4°C, and incubated with 50 ml of twofold serial
dilutions of the sample sera in a 1/5 dilution of PBS/MP/S supplemented with
0.05% Tween 20 (PBS/MP/S/T) overnight at 4°C. After three washes of the wells
with distilled water, they were incubated with 50 ml of a 1/1,000 dilution of
horseradish peroxidase-conjugated goat anti-mouse IgG solution (Protos Immu-
noresearch, Burlingame, Calif.) for 30 min at room temperature. After three
washes in water, bound conjugate was developed by incubation with 50 ml of
K-blue TMB substrate (Graphic Scientific). The reaction was stopped by the
addition of 50 ml of 2 M H2SO4, and readings of the optical density at 450 nm of
the reaction products were determined.
Mouse lung sections. One, 2, 4, and 8 weeks after intranasal delivery of the
pKUNbrep2 DNA, mice were euthanatized with CO2 and their lungs were
removed, rinsed in PBS, and fixed in 4% paraformaldehyde for 2 to 4 h at room
temperature. Whole lungs were stained with X-Gal (see above), post-fixed in
formalin, and paraffin embedded, and ;5-mm sections were prepared, mounted,
and photographed.
RESULTS
Ub-containing KUN replicon vectors. The Ub sequence (16)
was originally introduced into KUN replicon vectors (see Fig.
1A and 2) for two purposes: firstly, to improve the induction of
TABLE 1. Primers used in preparation of KUN replicon vectors and constructs
Primer Sequence (59339)a Restriction site used
Ub_F ggttctagatgcatacgcgttaCAGATATTCGTGAAGACT XbaI
Ub_R ggtactagtacgtaaggcgcGCCACCACGGAGACG SpeI
NS5dGDD_F CTG GTT AAC TGT GTG GTA AAG CCC TT
39UTRHDV GAGAACACAGGATCTGGGTCGGCATGGCATCT
SV40Pa_R ggcctcgaGCAATTGTTGTTGTTAACTT XhoI
CMV_F gcgcttaaGACATTGATTATTGACTAGTTA
CMV59UTR CGTTTAGTGAACCGAGTAGTTCGCCTGTGTGA
FMDV2A_R gtgacgcgtcggccGGGCCCTGGGTTGGA EagI
PacPst_F cgccctgcagccACCGAGTACAAGCCCA PstI
2AMluNsi_R ctggatgcatacgcgtcGGGCCCTGGGTTG NsiI
NsiIRES_F ggtatgcatagCGGGATCAATT NsiI
dNS1H3_R ccgaagcttgTCCAGTATCAGCATGCA SphI
NsiLacZ_F ccggatgcatggGTCGTCTTACAGCGTCGT NsiI
NsiLacZ_R cgcgatgcatgTTTTTGACACCAGACTAACT NsiI
a Nucleotides in capital letters represent the authentic KUN or cloned heterologous sequences (defined in the text), nucleotides in lowercase letters show artificial
sequences, and nucleotides in boldface show introduced restriction sites used in cloning.
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cytotoxic T-lymphocytes (CTL) against encoded HG product,
and secondly, to facilitate the formation of a precise amino
terminus of the HG product. Ub is specifically recognized by a
cellular protease complex and cleaved at its carboxy terminus
(5). Thus, cloning of an HG upstream of the Ub sequence (at
a unique MluI or NsiI site; Fig. 1A) will result in production of
a C20-HG-Ub fusion product containing the first 20 amino
acid residues encoded by the KUN open reading frame (C20)
at its amino terminus and those encoded by Ub at its carboxy
terminus. This (ubiquitinated) C20-HG-Ub product will pre-
sumably be more efficiently targeted to the cellular protea-
some-mediated major histocompatibility complex class I pre-
FIG. 1. Incorporation of the HDVr sequence into KUN replicons. (A) RNA-based KUN replicon constructs. Filled boxes represent translated regions of the KUN
replicon, as for the previously described C20DX2Arep plasmid (43). SP6, the SP6 RNA polymerase promoter. 59UTR and 39UTR represent the KUN 59 and 39
untranslated regions, respectively. Ub, mouse Ubiquitin gene (16). Hatched boxes indicate the FMDV-2A sequence (40). HDVr, the HDVr sequence (35) with its
cleavage site indicated by an arrow. pA, the SV40-derived polyadenylation signal sequence. Restriction sites used in construct preparation are as shown. Sequence of
the 39 UTR-HDVr junction, confirmed by sequencing, is indicated. (B) IF analysis with KUN anti-NS3 antibodies of BHK21 cells 24 h after transfection with equal
amounts of C20Ubrep or C20UbHDVrep in vitro-transcribed RNAs. In vitro transcription and transfection of KUN replicon RNA, as well as anti-NS3 IF analysis, were
performed as described previously (24, 25). (C) RT-PCR analysis of the KUN RNA transcripts. The RNA templates were either in vitro transcribed from the
C20UbHDVrep plasmid DNA (as described in reference 24 with omission of the synthetic cap analogue; lanes 2 and 3) or extracted from purified KUN virus grown
in Vero cells and decapped (24; lane 4). The RNA templates were purified by phenol-chloroform extraction and ethanol precipitation and were self-ligated with T4
RNA ligase (Pharmacia) at 17°C for 12 h in the reaction buffer (50 mM Tris-HCl [pH 7.5], 10 mM MgCl2, 10 mM ATP, 60 mg of bovine serum albumin/ml) (lanes
2 and 4). The resulting circular RNAs were then RT-PCR amplified across the 39 end-59 end junction by using One-Step RT-PCR System (Gibco BRL), essentially
as described by the manufacturer. The primers for RT-PCR were forward primer 59-GCTGCGAAGTGATCCATGTAA-39 (representing nucleotides 10582 to 10603
of the KUN 39UTR sequence; 24) and reverse primer 59-GGGCCCTCCTGGTTTCTT-39 (complementary to nucleotides 119 to 102 of the KUN core-59UTR region;
24). The size of the HDVr-pA sequence was 279 bp, and the expected sizes of RT-PCR products were 561 bp and/or 840 bp, depending on whether the HDVr cleavage
occurred or not. Lane 3, the product of RT-PCR from unligated in vitro-transcribed C20UbHDVrep RNA (negative control). The ;450- and ;700-bp fragments in lane 3
represent nonspecific amplification products. Lane 4 (see above), a positive control for the experiment; lane 1, 1-kb Plus DNA molecular size marker (Gibco BRL).
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sentation pathway similar to that described by Rodriguez et al.
(38). The insertion of an HG between the Ub and FMDV-2A
sequences (at a unique AscI site; Fig. 1A) will result in synthe-
sis of an HG-FMDV-2A fusion product with a precise HG
sequence-defined amino terminus (as described in references 4
and 5). A correct processing of encoded HG products from the
Ub-containing KUN replicon vectors was confirmed by RIP
analysis (data not shown), and the immunogenic potentials of
these vectors will be addressed elsewhere. For the purpose of
this study, Ub-containing vectors were used as intermediates
for construction of other vectors (Fig. 2).
Specific restriction of KUN replicon RNA by an encoded
HDVr. As a first step in the construction of DNA-based KUN
replicon vectors, the HDVr-pA cassette containing the HDV-
derived ribozyme and the SV40-derived transcription termina-
tion signal (see Materials and Methods) was inserted immedi-
ately downstream of the last nucleotide of the RNA-based
KUN replicon vector C20Ubrep, producing the C20UbHDVrep
construct (Fig. 1A). The number of cells positively transfected
with in vitro-transcribed C20UbHDVrep RNA was signifi-
cantly (;fivefold) higher than that detected after transfection
with the same amount of C20Ubrep RNA, as judged by im-
munofluorescent (IF) analysis with KUN anti-NS3 antibodies
(Fig. 1B). This is presumably indicative of higher infectivity
and/or replication efficiency of the C20UbHDVrep-derived
RNA, since we previously demonstrated that the number of
NS3-positive cells directly correlated with the amount of KUN
RNA accumulated in the replicon RNA-transfected cells (25,
26).
The increased efficiency of the C20UbHDVrep RNA is most
likely due to the HDVr cleavage-mediated formation of the
authentic KUN RNA 39 terminus, which has been shown to be
important for efficient initiation of RNA synthesis by positive-
strand RNA viruses (9). Other studies have found that the
extent of self-cleavage by HDVr depended on a specific RNA
conformation (46). To examine the catalytic activity of the
KUN replicon-encoded HDVr, KUN replicon RNA was in
vitro transcribed from the C20UbHDVrep DNA template,
self-ligated, and used for reverse transcription (RT)-PCR am-
plification across the 39 end-59 end junction (Fig. 1C). The
RT-PCR product amplified from the ligated C20UbHDVrep
RNA (Fig. 1C, lane 2) contained a 561-bp fragment corre-
sponding in size to the HDVr-cleaved RNA and identical to
the fragment amplified from the decapped and self-ligated
virion RNA (24) (Fig. 1C, lane 4). No RT-PCR fragment of the
same size was detected in the reaction with the unligated
C20UbHDVrep RNA template (Fig. 1C, lane 3), thus demon-
strating the specificity of the RT-PCR (see the legend to Fig.
1C). Sequencing of the corresponding RT-PCR products con-
firmed the authenticity of the KUN RNA 39 end formed by the
HDVr-mediated cleavage during the RNA preparation and/or
ligation. Overall, this experiment demonstrated the catalytic
activity of HDVr encoded in the KUN replicon construct, but
it did not define the extent of HDVr cleavage nor whether this
cleavage occurred during RNA preparation in vitro and/or
after RNA transfection into cells. It is also possible that the
C20UbHDVrep-derived RNA with uncleaved HDVr is more
stable and therefore may be more infectious.
DNA-based KUN replicon vectors. To enable RNA poly-
merase II-mediated in vivo transcription of the KUN replicon-
encoding plasmid DNA, the KUN replicon sequence was
placed under the control of the CMV-derived promoter (8)
(Fig. 2). To ensure formation of precise 59 termini in KUN
replicon transcripts, KUN DNA-based constructs were engi-
neered so that the last nucleotide of the CMV promoter was
immediately followed by the first nucleotide of the KUN se-
quence (see Materials and Methods).
The pKUNrep1 vector is a DNA-based equivalent of the
C20UbHDVrep construct (Fig. 1A). The pKUNrep2 vector
differs from pKUNrep1 only by the absence of the Ub se-
quence (Fig. 2). Both pKUNrep1 and pKUNrep2 were de-
signed for transient gene expression. The DNA-based vectors
pKUNrep3 and pKUNrep4, which encode a PAC selection
marker (42) which confers resistance to the antibiotic puromy-
cin, were designed for the generation of cell populations stably
expressing the encoded proteins (see Materials and Methods).
An HG cloned into a unique MluI or NsiI site of the pKUN-
rep3 vector was initially translated as a part of a single polypro-
tein. The subsequent cleavages by two flanking FMDV-2A
autoproteases (Fig. 2) should result in the release of the HG
FIG. 2. DNA-based KUN replicon vectors. Most of the designations are as in Fig. 1. CMV, the eukaryotic CMV-derived immediate-early enhancer/promoter region
(8). Ub- and FMDV-2A-mediated cleavages are indicated by arrows. Sequence of the CMV-59UTR junction, confirmed by sequencing, is shown. dGDD with an arrow
(in pKUNrep2) indicates the position of the deletion of the RNA polymerase motif GDD (26). PAC, the PAC gene (42). IRES, the sequence of the encephalomy-
elocarditis virus IRES. Restriction sites used in construct preparation are as shown.
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fusion product containing the FMDV-2A peptide (;19 amino
acid residues; 40) at its carboxy terminus. In the dicistronic
pKUNrep4 vector, on the other hand, translation of the HG is
separated from translation of the rest of the polyprotein by an
IRES (Fig. 2), allowing production of the HG product with a
precise carboxy terminus determined by its termination codon.
The amino termini of HG products from both pKUNrep3 and
pKUNrep4 vectors, generated by the FMDV-2A cleavage (39,
40), will contain only two to five additional vector-derived
amino acids, depending on the choice of the cloning site.
Evidence of self-amplification of in vivo-transcribed KUN
replicon RNA. To demonstrate self-amplification of the in
vivo-transcribed KUN replicon RNAs, as well as to estimate
the effect of this amplification on the level of gene expression,
a comparison of RNA and protein syntheses from the DNA-
based KUN replicon vector pKUNrep2 and from the same
vector but with a deletion of the RNA polymerase motif GDD
in pKUNrep2(dGDD) (Fig. 2) was performed. The GDD de-
letion was previously shown to completely abolish KUN RNA
replication (26). Therefore, the KUNrep2(dGDD) RNA could
only be produced via transcription from the transfected DNA
by cellular RNA polymerase II, resembling RNA synthesis
from conventional plasmid DNA expression vectors.
Initially, we compared the relative amounts of KUN replicon
RNA produced in BHK21 cells 36 h after transfection with
equal amounts of the pKUNrep2 (RNA replication compe-
tent) or pKUNrep2(dGDD) (RNA replication defective)
DNAs using Northern blot hybridization analysis. The amount
of KUN replicon RNA produced from the former was signif-
icantly (;fivefold) higher than that produced from the latter
(Fig. 3A). We then examined the expression of one of the
vector proteins (NS3) in BHK21 cells transfected with the
pKUNrep2 or pKUNrep2(dGDD) constructs, using RIP anal-
ysis with KUN anti-NS3 antibodies (Fig. 3B). Similarly to the
synthesis of replicon RNA, a significantly higher (;sixfold)
amount of NS3 was produced in the pKUNrep2-transfected
cells compared to that produced in the pKUNrep2(dGDD)-
transfected cells, as determined by quantitative phosphorim-
ager analysis (Fig. 3B, compare lanes 1 and 3). Importantly,
NS3 expression in cells transfected with the pKUNrep2 DNA
for 30 h was not apparently reduced in the presence of ACD,
an inhibitor of DNA-dependent RNA synthesis (Fig. 3B, com-
pare lanes 1 and 2), while that for pKUNrep2(dGDD) was
(Fig. 3B, compare lanes 3 and 4). The small amount of labeled
NS3 in lane 4 was presumably translated from replicon RNA
transcribed prior to addition of ACD.
Comparative analysis of transient HG expression kinetics
by KUN replicon and other DNA-based vectors. The b-Gal
gene was used as a reporter HG for comparative analysis of
protein expression levels from the DNA-based KUN replicon
vector and other DNA-based vectors. The KUN replicon con-
structs pKUNbrep2 and pKUNbrep2(dGDD) were prepared
by cloning b-Gal into pKUNrep2 and pKUNrep2(dGDD) vec-
tors, respectively (see Materials and Methods). The levels of
b-Gal expression in BHK21 cells, transfected with the same
amounts of pKUNbrep2, pKUNbrep2(dGDD), pSCAb (SFV
replicon-based construct; 14) and pCMVb (a conventional
plasmid DNA expression construct; Clontech) plasmid DNAs,
were compared at different times posttransfection. Transfec-
tion efficiencies, determined by counting X-Gal-staining-posi-
tive cells of duplicate parallel transfection samples, were
;40% for all DNA constructs, except for pCMVb DNA (;50
to 60%), probably due to its relatively small size (7.2 kb versus
16.5 kb for pKUNbrep2 and 14.5 kb for pSCAb DNAs).
Because of a delay of ;16 h in detectable b-Gal expression
from the pKUNbrep2 DNA, the comparative expression re-
sults are shown commencing at 24 h (1 day) posttransfection
(Fig. 4). To account for the noncytopathic nature and persis-
tence of replication of KUN replicon vectors, the transfected
cells were allowed to propagate continuously during the entire
experiment by passaging them into larger plates 2 days after
the initial transfection (see legend of Fig. 4). The level of b-Gal
expression in continuously propagating BHK21 cells trans-
fected with the KUN replicon DNA construct pKUNbrep2
steadily increased with time after transfection. Five days after
the initial transfection, this level was ;18-fold higher than that
after transfection with the SFV DNA construct pSCAb and
;7- to 10-fold higher than that generated by the conventional
plasmid DNA construct pCMVb (Fig. 4). Most of the
pKUNbrep2-transfected cells appeared healthy and formed
b-Gal-expressing cell colonies, thus demonstrating transfer of
the replicating KUNbrep2 RNA into daughter cells during cell
division. In contrast, b-Gal expression from the pSCAb DNA
was significantly reduced by day 5 posttransfection, presumably
due to the vector-induced death of the expressing cells. Nota-
bly, similar expression kinetics for pSCAb construct was re-
ported by DiCiommo and Bremner (14). In addition, b-Gal
expression from the pCMVb and pKUNbrep2(dGDD) con-
struct, both noncytopathic and RNA replication defective, did
not increase from day 2 to day 5 posttransfection (Fig. 4),
demonstrating that the corresponding ;fivefold increase in the
b-Gal level detected in pKUNbrep2 DNA-transfected cells
FIG. 3. Comparison of RNA and protein syntheses from the RNA replication-competent and RNA replication-defective KUN replicon DNA vectors. (A) Northern
blot hybridization analysis of total RNA isolated from BHK21 cells 36 h after transfection with equal amounts of pKUNrep2 (lane 1) or pKUNrep2(dGDD) (lane 2)
plasmid DNAs, or untransfected cells (lane 3). The probe was a [32P]dCTP-labeled cDNA fragment representing the last 761 nucleotides of the KUN genome (24).
(B) RIP analysis with KUN anti-NS3 antibodies of BHK21 cells radiolabeled for 1 h at 30 h after transfection with pKUNrep2 (lanes 1 and 2) or pKUNrep2(dGDD)
(lanes 3 and 4) plasmid DNAs. Shown are RIP samples from cells labeled in the absence (2) (lanes 1 and 3) or presence (1) (lanes 2 and 4) of ACD. The specificity
of KUN anti-NS3 antibodies in RIP and IF analyses was demonstrated previously (45). Relative phosphorimager counts of the radiolabeled NS3 bands in corresponding
RIP samples are shown with the background level deducted. DNA transfection, Northern blot hybridization, protein labeling, ACD treatment, and RIP procedures were
performed as described in Materials and Methods.
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was indeed due to the replicon RNA self-amplification rather
than only to propagation of the b-Gal-expressing cells.
Transient and stable HG expression from DNA-based KUN
replicon vectors in different cell lines and in vivo. Transient
expression of the reporter gene b-Gal from transfected
pKUNbrep2 DNA was demonstrated in a number of cell lines
of different origin (Fig. 5A). To examine the efficacy of puro-
mycin-selectable DNA-based KUN replicon vectors pKUNrep3
and pKUNrep4 for the generation of cell cultures stably ex-
pressing HGs, the corresponding b-Gal-recombinant con-
structs pKUNbrep3 and pKUNbrep4 were prepared (see Ma-
terials and Methods). Several cell lines stably expressing b-Gal
after transfection with pKUNbrep3 or pKUNbrep4 plasmid
DNAs and subsequent puromycin selection were successfully
established (Fig. 5B and Table 2). Significantly, no b-Gal ex-
pression-negative cells were detected and the expression levels
remained high throughout passaging (see Table 2). Maximum
production of b-Gal in selected BHK21 cells was ;200 pg/cell
in the first two or three passages, which was similar to the
amount of b-Gal per expressing cell produced during transient
expression from pKUNbrep2 DNA by 48 h after transfection.
Importantly, the expression levels decreased by only ;20 to
25% after extensive cell passaging (Table 2), indicating the
highly stable nature of HG expression directed by the DNA-
based KUN replicon vectors. We have previously observed
similar results on the stability of HG expression from the
selectable RNA-based KUN replicon vector C20DX2ArepNeo
(43). The level of b-Gal expression from pKUNbrep4 con-
struct was slightly lower than that obtained from pKUNbrep3
construct in selected BHK21 cells (see Table 2).
The potential of KUN replicon-based vectors for delivery
and expression of HGs in vivo was evaluated by intranasal
administration of pKUNbrep2 DNA into BALB/c mice (see
Materials and Methods). Expression of b-Gal was detected in
FIG. 4. Comparative analyses of transient b-Gal expression from the KUN
replicon [pKUNbrep2, pKUNbrep2(dGDD); see Materials and Methods],
pSCAb (SFV replicon-based; 14), and pCMVb (conventional plasmid; Clon-
tech) DNA constructs. BHK21 cell monolayers (;1.3 3 105 cells in 16-mm-
diameter wells of 24-well plates) were transfected with ;0.8 mg of corresponding
DNAs and incubated until reaching confluency (;2 days posttransfection). The
cells were then trypsinized and transferred into larger plates to allow continuous
cell division. Forty percent of the trypsinized cells were transferred into 35-mm-
diameter plates, allowed to propagate, and assayed for b-Gal activity at day 3
after initial transfection. Fifty percent of the trypsinized cells were transferred
into 60-mm-diameter plates, allowed to propagate, and assayed for b-Gal activity
at day 5 after initial transfection. U*, the amounts of biochemically active b-Gal
protein, in units of the enzymatic activity, produced in the total volume of each
cell lysate collected from 16-mm-diameter wells (days 1 and 2), 35-mm-diameter
plates (day 3), and 60-mm-diameter plates (day 5). The values are the means 6
standard deviation for triplicate experiments.
FIG. 5. Expression of b-Gal in different cell lines using DNA-based KUN
replicon vectors. (A) Transient b-Gal expression in indicated cell lines, detected
by X-Gal staining 30 to 40 h after transfection with the pKUNbrep2 DNA. (B)
Stable b-Gal expression in different cell lines at indicated passages after trans-
fection with the pKUNbrep3 (BHK21, Vero, 293, HEp-2 cells) or pKUNbrep4
(A172 cells) DNAs and subsequent puromycin selection. DNA transfection and
puromycin selection of cell cultures were performed as described in Materials
and Methods.
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epithelial cells lining the lung airways at 1, 2, 4, and 8 weeks
after inoculation (Fig. 6), clearly demonstrating the ability of
KUN replicon DNA to direct prolonged expression of HGs in
vivo.
Induction of anti-b-Gal-specific antibodies in mice immu-
nized with b-Gal-encoding KUN replicon DNA. The ability of
the KUN replicon-based plasmid DNA to induce specific an-
tibodies against the encoded b-Gal protein after i.m. immuni-
zation was examined in BALB/c mice. Anti-b-Gal antibody
levels induced by pKUNbrep2 DNA were compared with
those induced by SFV replicon-based and conventional plas-
mid DNA-based b-Gal-encoding vectors. The anti-b-Gal anti-
body responses in mice immunized twice i.m. with 25 mg of
either pKUNbrep2, pSCAb, pCMVb, or control pKUNrep2
DNAs were examined by ELISA (per Materials and Methods).
The antibody levels were low or undetectable at 4 weeks
postpriming with all the DNA constructs but increased signif-
icantly at 8 and 11 weeks postpriming (3 and 6 weeks post-
booster, respectively) in all mice immunized with pKUNbrep2
DNA, but only in one out of three and in two out of three mice
immunized with pSCAb and pCMVb DNAs, respectively (Fig.
7A). Figure 7B shows ELISA titration results for the 8-week
sera from the individual mice immunized with the pKUNbrep2
or pKUNrep2 DNAs. Interestingly, no detectable antibody
responses against the KUN vector-encoded NS5 protein were
induced in mice immunized with pKUNrep2 or pKUNbrep2
DNAs (data not shown).
DISCUSSION
We have described the construction and potential applica-
tions of the DNA-based KUN replicon vectors, which allow
efficient in vivo synthesis of KUN replicon RNAs from the
corresponding plasmid DNAs. This is a further step in the
development of the KUN replicon-based gene expression sys-
tem (25, 27, 43) and, to our knowledge, is the first demonstra-
tion of the production of a replicating flavivirus RNA from
plasmid DNA in vivo. The use of DNA-based vectors elimi-
nates expensive and cumbersome RNA preparation and han-
dling steps and allows utilization of conventional protocols for
delivery of plasmid DNA.
KUN replicon sequence in the DNA-based vectors was
placed under transcriptional control of the CMV-derived pro-
moter and SV40-derived transcription termination signal (Fig.
2), allowing KUN replicon RNAs to be transcribed by cellular
RNA polymerase II. The importance of precise 59 and 39
termini for infectivity and/or replication efficiency was re-
ported for different positive-strand RNA virus genomes (6, 9).
Therefore, the CMV promoter sequence was placed immedi-
ately upstream of the first nucleotide of the KUN sequence,
thus ensuring the formation of authentic KUN 59 ends during
KUN replicon RNA transcription. To facilitate as well the
formation of authentic KUN 39 ends, the HDVr sequence (35)
was incorporated immediately downstream of the KUN repli-
con sequence (Fig. 1 and 2), as reported for other viral RNA
transcripts produced from DNA-based constructs (15, 21,
22, 33). The catalytic activity of HDVr was demonstrated
for the KUN replicon RNA in vitro transcribed from the
C20UbHDVrep DNA (see Results and Fig. 1).
Efficient self-replication of in vivo-transcribed KUN replicon
RNAs was demonstrated by comparison of RNA and protein
syntheses from the KUN replicon DNA constructs and their
corresponding RNA-replication-defective mutants with a de-
leted GDD motif. Thus, the levels of RNA and protein syn-
theses from the RNA replication-competent vector pKUNrep2
were five- to sixfold higher than those from the nonreplicating
vector pKUNrep2(dGDD) (Fig. 3). Also, the total amount of
b-Gal produced in continuously propagating cells from the
pKUNbrep2 DNA increased by ;20-fold from day 1 to day 5
after transfection, compared to no apparent increase in b-Gal
expression in cells transfected with the RNA replication-de-
fective pKUNbrep2(dGDD) DNA construct during the same
time period (Fig. 4). Apparently, noncytopathic replication of
KUN replicon RNA allowed the transfected cells to divide
normally and to transfer replicon RNA into daughter cells
where it continued its self-amplification, resulting in a signifi-
cant increase in total HG expression. Although replicon RNA
produced from the SFV DNA-based construct pSCAb is also
capable of self-amplification, its replication and corresponding
increase in HG expression is limited to only ;3 days due to the
induction of strong CPE in the host cells. On the other hand,
the expression from noncytopathic pCMVb and pKUNbrep2
(dGDD) constructs, producing nonreplicating mRNAs by nu-
clear transcription, did not increase after day 2 posttransfec-
tion (Fig. 4), thus reflecting the enhancing effect of cytoplasmic
self-amplification (of replicon-based vectors) on levels of gene
expression.
Stable expression of b-Gal reporter was examined in differ-
ent cell cultures transfected with pKUNbrep3 or pKUNbrep4
DNAs and subsequently selected with puromycin (Table 2).
The slight variation in the levels of b-Gal expression from
pKUNbrep3 DNA in distinct cell lines was probably due to
differences in replication efficiency of KUN replicon RNA
and/or cellular conditions at the time of the analysis. On the
other hand, in the selected BHK21 cells, b-Gal expression
from the pKUNbrep4 construct was ;20 to 30% lower than
that from the pKUNbrep3 construct. This difference could
result from a less efficient replication of the pKUNbrep4-
derived RNA possibly due to a less efficient initiation of trans-
lation of KUN nonstructural proteins from the IRES com-
pared with that from the native KUN 59 end. Replication of
KUN replicon RNA may also be inhibited by an extended
IRES RNA secondary structure. Clearly, further investigations
including direct comparison of the replication efficiencies of
the RNAs produced from pKUNrep3 and pKUNrep4 vectors
are required to make definite conclusions.
The levels of gene expression from the DNA-based KUN
replicon vectors were comparable with those achieved by the
most efficient cytopathic SFV replicon vectors in transient ex-
TABLE 2. Expression of b-Gal in cells using DNA-based
KUN replicon vectors
DNA construct
(expression type)
Cell
type
Cell
passage
Amt of b-Gal
(pg/cell)a
pKUNbrep2 (transient) BHK21 186 6 27
pKUNbrep3 (stable) BHK21 2 194 6 9
BHK21 3 198 6 14
BHK21 13 153 6 4
BHK21 22 156 6 7
Vero 10 153 6 6
HEp-2 15 154 6 22
293 20 122 6 4
pKUNbrep4 (stable) BHK21 6 130 6 6
A172 8 140 6 12
a Amounts of b-Gal were determined by using the b-Galactosidase Enzyme
Assay System (Promega) by comparison with b-Gal concentration standards. To
calculate b-Gal amounts per expressing cell, the amounts of b-Gal detected in
the total volume of cell lysates were divided by the number of expression-positive
cells at 48 h posttransfection in transient-expression experiments or by the total
number of cells in stably expressing (100% b-Gal positive) cultures at indicated
passages. The values are the means 6 standard deviations for triplicate experi-
ments.
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pression experiments (7) and significantly higher than those
reported for noncytopathic SIN replicon vectors (1). The se-
lectable SIN replicon vectors were isolated by selection of
PAC-encoding mutants adapted to replication in BHK21 cells
in the presence of puromycin. These mutants replicated ;50-
to 100-fold less efficiently than the wild-type cytopathic SIN
replicon RNA and produced only ;1 pg of b-Gal per cell (1,
17). Pairing of the noncytopathic SIN puromycin-selectable
replicon RNA with the G418-selectable SIN DI vectors (re-
quired double-antibiotic selection) increased the expression
level to ;30 pg per cell (1), which is still at least fivefold lower
than the expression levels achieved by the single KUN replicon
vector (;150 pg/cell; Table 2). Importantly, the level of HG
expression in KUN replicon-derived stable cell lines was re-
duced only slightly during the extensive cell passaging (Table
2), indicating high stability of KUN replicon-directed gene
expression and suggesting a potential application of such KUN
replicon-derived cell cultures for large-scale continuous pro-
duction of heterologous proteins.
Another useful feature of KUN replicons is their ability to
replicate efficiently in a broad range of host cells without pro-
ducing any apparent CPE. Thus, using KUN replicon DNA-
based vectors, we were able to express HGs (stably and/or
transiently) in different cell lines, including BHK21, Vero,
HeLa, HepG2, HEp-2, 293, and A172 (Fig. 5A and B), as well
as L929 (mouse fibroblasts) and Jurkat (human lymphoma)
cells (unpublished data). Noticeably, a broad host range was
also observed for KUN replicon RNA- and VLP-based vectors
(unpublished data). In addition, we demonstrated expression
of the b-Gal reporter gene in mouse lung epithelial cells for at
least 8 weeks following the intranasal inoculation of mice with
the b-Gal-encoding KUN replicon DNA (Fig. 6). Although we
did not compare the longevity of in vivo expression with other
replicon-based vectors, the reported studies for alphavirus vec-
tors have been limited to only 5 to 14 days (2, 15, 20). The
ability to direct prolonged noncytopathic gene expression in
different host cells is a unique property of KUN replicon vec-
tors, presumably reflecting the inherent nature of their noncy-
FIG. 6. b-Gal expression in mouse lung epithelial cells at indicated times after intranasal inoculation with the DNA-based KUN replicon construct pKUNbrep2.
Control panel shows a lung section of a mouse inoculated with the pKUNrep2 DNA. DNA administration and preparation of lung sections were performed as described
in Materials and Methods.
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topathicity (25, 26). Similarities in the levels of HG (b-Gal)
expression after transient transfection with the KUN replicon
construct and in selected stably expressing cells also indicate
that noncytopathicity of KUN replicons is defined in their
original sequence, rather than being acquired by adaptive mu-
tations during the selection of replicon-expressing cells.
Prolonged high-level HG expression afforded by the KUN
replicon vectors discussed above may be advantageous in the
context of vaccine applications for maintaining long-lasting
immunity. KUN b-Gal-encoding DNA construct pKUNbrep2
induced appreciable levels of anti-b-Gal antibodies for at least
11 weeks in all the immunized mice (Fig. 7A and B), and in a
separate experiment we were able to detect antibodies to green
fluorescent protein (GFP) over a year after immunization with
GFP-recombinant KUN VLPs (unpublished results). The
equimolar synthesis of encoded HG and KUN nonstructural
proteins by the KUN replicon constructs raises a concern
about the immune response against the vector-encoded pro-
teins. Surprisingly, we could not detect antibodies when tested
against one of the KUN proteins, NS5 (see Results). It is
possible that in the context of noncytopathic expression, the
tight association of the KUN nonstructural proteins in the
membrane-bound RNA replication complex (30, 45) pre-
vented their efficient presentation to the immune system. It is
also possible that b-Gal expressed from the KUN replicon
construct could be more immunogenic than NS5. Another
potentially beneficial factor of using KUN replicon constructs
as vaccines is the synthesis of double-stranded RNA during the
KUN RNA replication, which is known to facilitate production
of immune-enhancing cytokines (44) and to activate protein
kinase-dependent antigen presentation pathways (13). In ad-
dition, flaviviruses, unlike alphaviruses, have been shown to
up-regulate expression of major histocompatibility complex
class I and class II molecules (28, 31, 41). Whether the KUN
replicon-based vectors will also induce such up-regulation is
not yet known, and we intend to address this, as well as other
aspects of KUN replicon-directed immune responses, in future
studies.
In conclusion, we have developed highly efficient DNA-
based KUN replicon vectors allowing prolonged high-level ex-
pression of HGs in cells and in laboratory animals. We believe
that these vectors should prove their usefulness in a variety of
applications both in vitro and in vivo.
FIG. 7. Induction of b-Gal-specific antibodies in mice after i.m. immunization with b-Gal-encoding plasmid DNA constructs. (A) b-Gal-specific IgG responses in
a 1/800 dilution of sera from BALB/c mice 4, 8, and 11 weeks after i.m. immunization with pKUNrep2, pKUNbrep2, pSCAb, and pCMVb plasmid DNA constructs
(as per Materials and Methods). ELISA readings for individual mouse sera are shown by open squares (preimmune sera [pr]) and filled squares (immunized sera; 4,
8, and 11 weeks postpriming). Horizontal lines show the averages for each group. (B) b-Gal-specific IgG responses induced in individual sera of BALB/c mice 8 weeks
post i.m. immunization (3 weeks postboost) with the pKUNbrep2 and control pKUNrep2 plasmid DNAs. OD450, optical density at 450 nm.
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